Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Treatment with an indefinite course of osimertinib dramatically improves progression-free survival for patients with stage 3 non-small cell cancer, according to the results of the LAURA trial. The median PFS was 39.1 months in the osimertinib group, compared to 5.6 months with the placebo group.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Jacquelyn Cobb
Associate Editor
McKenzie Prillaman
McKenzie Prillaman
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging an attack from natural killer cells in an animal model, a study led by UT Southwestern Medical Center researchers shows. The findings, published in the Journal for ImmunoTherapy of Cancer, could lead to new types of immunotherapy that rely on this novel strategy.
Jacquelyn Cobb
Associate Editor
McKenzie Prillaman
McKenzie Prillaman
Reporter

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login